Call for grant applications Work package 4: Promising innovative therapies (phase 2)

The intended therapy intervenes on neurodegenerative processes that lead to dementia. By slowing down or stopping neurodegenerative processes, dementia can be postponed or prevented. This may also involve therapies that can prevent sequelae of the degenerative process. 

Therapies include pharmacological interventions, technologies and digital interventions, and neuromodulation. The therapy is currently in the proof-of-concept phase (TRL3) or in one of the development phases (TRL 4-5-6, as formulated by the RVO). With the project you focus on advancing the therapy towards the demonstration phase (TRL 7 and higher) or at least one TRL higher than the original level.

For pharmacological interventions, this corresponds to obtaining an in vitro PoC, initial preclinical studies and a pilot drug. The aim here is to take the drug at least to the next stage of development, with the ultimate goal of getting the drug ready for a phase 1 clinical trial. In the case of drug development, the phase 1 clinical trial corresponding to TRL 6 is outside the scope of this call.

In addition, you work on or build upon a business case, business structure, and the protection of intellectual property.